Poster Presentation Archives | Page 5 of 5 | Vor Bio

G-CSF/Plerixafor Dual-Mobilized Donor Derived CD33CAR T-Cells as Potent and Effective AML Therapy in Pre-Clinical Models

ASH Annual Meeting 2021 – Poster Presentation 1716 […]

Read More… from G-CSF/Plerixafor Dual-Mobilized Donor Derived CD33CAR T-Cells as Potent and Effective AML Therapy in Pre-Clinical Models

Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knockout While Maintaining High Engraftment Potential and Safety

ASH Annual Meeting 2021 – Poster Presentation 2939 […]

Read More… from Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knockout While Maintaining High Engraftment Potential and Safety

Knock Out of CD123 or CLL-1 by CRISPR-Cas9 Editing From Human Hematopoietic Stem Cell Transplantations Provide New Possibilities for Increasing Therapeutic Index and Safety for AML Treatment

ASH Annual Meeting 2021 – Poster Presentation 3818 […]

Read More… from Knock Out of CD123 or CLL-1 by CRISPR-Cas9 Editing From Human Hematopoietic Stem Cell Transplantations Provide New Possibilities for Increasing Therapeutic Index and Safety for AML Treatment

An NFAT Promoter–Based Fluorescent Jurkat Cell Platform for High- Throughput Screening of Chimeric Antigen Receptor (CAR) Constructs

SITC – 2021 – Poster Presentation 115 […]

Read More… from An NFAT Promoter–Based Fluorescent Jurkat Cell Platform for High- Throughput Screening of Chimeric Antigen Receptor (CAR) Constructs

Construction and Evaluation of Interleukin 3 (IL3)-Zetakine–Redirected Cytolytic T Cells for Treatment of CD123-Expressing Acute Myeloid Leukemia

SITC – 2021 – Poster Presentation 871 […]

Read More… from Construction and Evaluation of Interleukin 3 (IL3)-Zetakine–Redirected Cytolytic T Cells for Treatment of CD123-Expressing Acute Myeloid Leukemia

In Depth Assessment of Off-target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia

ESGCT – 2021 – Poster Presentation P112 […]

Read More… from In Depth Assessment of Off-target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia

Rigorous Assessment of Off-Target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia

ASGCT – 2021 – Poster Presentation 858 […]

Read More… from Rigorous Assessment of Off-Target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia